New oral anticoagulants do not differ significantly in safety and efficacy from enoxaparin
How to Cite
OrthoEvidence. New oral anticoagulants do not differ significantly in safety and efficacy from enoxaparin. ACE Report. 2013;2(8):21. Available from: https://myorthoevidene.com/AceReport/Report/4450
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisonsBMJ. 2012 Jun 14;344:e3675. doi: 10.1136/bmj.e3675
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
A meta-analysis of 16 randomized trials (38747 patients) was conducted to investigate the effects of new oral anticoagulants (rivaroxaban, dabigatran, and apixaban), compared with standard enoxaparin, for prophylaxis against venous thromboembolism after total hip or knee replacement surgery. After investigating relative risks of symptomatic venous thromboembolism, clinically relevant bleeding, and...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE